Bortezomib

Introduction

Bortezomib is a proteasome inhibitor used primarily in the treatment of multiple myeloma and certain types of lymphoma. It works by blocking the proteasome, a cellular complex responsible for degrading proteins that regulate cell cycle and apoptosis. This leads to the accumulation of pro-apoptotic factors and inhibition of cancer cell growth.

Uses

Bortezomib is used for:

Treatment of multiple myeloma, particularly in patients who have received at least one prior therapy.
Treatment of relapsed or refractory mantle cell lymphoma.
As part of combination therapy for various hematological malignancies.

It is usually administered when other treatments have failed or are not suitable for the patient.

Brand Name	Bortezomib
Type
Weight
Generic	Bortezomib
Manufacturer
Available in	English বাংলা

Mechanism of Action

Bortezomib inhibits the proteasome, an enzyme complex that degrades ubiquitinated proteins. By blocking this process, bortezomib prevents the breakdown of proteins that regulate apoptosis and cell cycle progression, leading to an accumulation of pro-apoptotic factors and induction of cell death in cancer cells. This disruption helps to suppress tumor growth.

How Long Does It Take to Work?

Patients may start to see clinical improvement within a few weeks of starting bortezomib therapy. However, the full therapeutic effects can take several months to become evident. Response times can vary based on the type of cancer, overall health, and other individual factors.

Absorption

Bortezomib is administered intravenously, ensuring direct entry into the bloodstream and bypassing issues related to gastrointestinal absorption. For the subcutaneous form, absorption is generally consistent and not significantly impacted by food intake.

Route of Elimination

Bortezomib is primarily eliminated through metabolism in the liver. The drug is excreted mostly in feces, with a smaller amount excreted in urine. The liver’s cytochrome P450 system is involved in its metabolic processing.

Dosage

The recommended dose of Bortezomib is 1.3 mg/m2/dose administered as a 3 to 5 second bolus intravenous and subcutaneous injection twice weekly for 2 weeks (Days 1, 4, 8, and 11) followed by a 10-day rest period (Days 12-21). For extended therapy of more than 8 cycles, Bortezomib may be administered on the standard schedule or on a maintenance schedule of once weekly for 4 weeks (Days 1, 8, 15, and 22) followed by a 13-day rest period (Days 23 to 35).

Bortezomib retreatment may be considered for patients with multiple myeloma who has previously responded to treatment with Bortezomib and who has relapsed at least 6 months after completing prior Bortezomib treatment. Treatment may be started at the last tolerated dose. Bortezomib is for intravenous or subcutaneous use only. Bortezomib should not be administered by any other route.

The dosage of bortezomib depends on the specific condition being treated, the patient's overall health, and whether it is used alone or in combination with other drugs. Typical dosages include:

For multiple myeloma: 1.3 mg/m² intravenously or subcutaneously on days 1, 4, 8, and 11 of a 21-day cycle.
For mantle cell lymphoma: 1.3 mg/m² intravenously on days 1, 4, 8, and 11 of a 21-day cycle.

Dosage adjustments may be required based on tolerance and response.

Administration

Bortezomib can be administered either intravenously or subcutaneously. The intravenous route involves a slow infusion over 3 to 5 minutes. For subcutaneous administration, the injection is usually given in the abdominal region. It is important to follow the specific administration guidelines provided by the manufacturer or healthcare provider.

Side Effects

Common side effects of bortezomib include:

Fatigue and weakness
Nausea, vomiting, and diarrhea
Peripheral neuropathy, including tingling, numbness, and pain
Thrombocytopenia and neutropenia
Fever and infections

Side effects can vary in severity and may require management or dose adjustments.

Toxicity

Potential toxicity includes:

Severe peripheral neuropathy, which may require dose reduction or discontinuation.
Severe myelosuppression, including thrombocytopenia and neutropenia.
Risk of reactivation of hepatitis B in patients with a history of hepatitis B infection.

Regular monitoring and dose adjustments can help manage toxicity.

Precautions

Precautions include:

Regular monitoring of blood cell counts to manage potential myelosuppression.
Monitoring for signs of peripheral neuropathy and adjusting treatment as needed.
Ensuring proper hydration and managing gastrointestinal side effects.

Patients with liver impairment or a history of hepatitis B should be monitored closely.

Interaction

Bortezomib may interact with:

Drugs that affect liver enzyme activity, potentially altering bortezomib levels.
Other medications that may exacerbate peripheral neuropathy.

It is important to inform healthcare providers of all medications and supplements being used to avoid potential interactions.

Disease Interaction

Use bortezomib with caution in patients with:

Active infections or those at high risk of infections.
Severe liver impairment, as the drug is metabolized in the liver.
Pre-existing peripheral neuropathy.

Regular monitoring and dose adjustments may be required for these conditions.

Drug Interaction

Drug interactions include:

Potential interactions with other drugs that affect blood cell counts or liver enzymes.
Increased risk of peripheral neuropathy with other neurotoxic drugs.

Always consult a healthcare provider for guidance on managing drug interactions.

Food Interactions

There are no significant food interactions with bortezomib. However, maintaining a balanced diet and managing side effects such as nausea or diarrhea can be important for overall treatment effectiveness and comfort.

Pregnancy Use

Bortezomib is classified as a Category D drug for pregnancy, indicating that it may cause harm to the fetus. It should be used during pregnancy only if the potential benefits outweigh the risks. Women of childbearing potential should use effective contraception during treatment.

Lactation Use

The safety of bortezomib during lactation is not well established. Due to potential risks to the infant, breastfeeding is generally not recommended during bortezomib therapy. Discuss with a healthcare provider to determine the best approach.

Acute Overdose

Acute overdose of bortezomib may exacerbate side effects such as severe myelosuppression or neuropathy. Treatment is symptomatic and supportive. Seek immediate medical attention in the case of an overdose.

Contraindication

Bortezomib is contraindicated in patients with:

Known hypersensitivity to bortezomib or any of its components.
Severe hepatic impairment without dose adjustment.

Ensure to review patient history and health conditions to determine if bortezomib is appropriate.

Use Direction

Follow the prescribed dosage and administration instructions provided by the healthcare provider or product labeling. Regular monitoring and adherence to treatment schedules are essential for effective therapy and management of side effects.

Storage Conditions

Store bortezomib at room temperature, away from light and moisture. Keep it out of reach of children. For specific storage instructions, refer to the product labeling or consult a pharmacist.

Volume of Distribution

The volume of distribution for bortezomib is approximately 1.5 L/kg. This indicates that the drug distributes relatively well into body tissues and fluids, influencing its therapeutic and side effect profile.

Half Life

The terminal half-life of bortezomib is approximately 40 to 60 hours. This extended half-life supports its dosing schedule, which typically involves administration on specific days of a treatment cycle.

Clearance

Bortezomib is primarily cleared through metabolism in the liver, with excretion occurring via feces and, to a lesser extent, urine. The clearance rate can be affected by liver function and other patient-specific factors.

See in details version Bortezomib also Bortezomib in bangla